Catalyst Wire Dossier Catalyst Wire Dossier

acalabrutinib (ACP-196)

acalabrutinib · Acerta Pharma BV
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for acalabrutinib (ACP-196), covering 2018-10-19 to 2018-10-19. Get the full timeline:

Most recent: Clinical Trial Update: An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma [Phase 2]

See pricing